Sana Biotechnology, Inc.
SANAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. With a market capitalization of $1.15B, it sits in small-cap territory. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Market Cap
$1.15B
Beta
2.13
P/E (TTM)
—
P/E (Fwd)
-6.94
EPS (TTM)
$-0.75
EPS (Fwd)
$-0.56
ROE
-152.9%
ROA
-29.2%
Cash
$160.5M
Total Debt
$80.9M
Free CF
$4.1M
52W Change
27.5%
Annual Financials
Cash vs Debt
Where SANA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SANA finished 12.43% above its 150-day moving average ($3.46) and 5.14% above its 200-day moving average ($3.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SANA overbought or oversold?
At the September 3, 2026 close, SANA's RSI(14) was 55.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Sana Biotechnology, Inc. holds $160.5M in cash against $80.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $4.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -152.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, SANA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing SANA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.